Entera Bio Ltd. — Investor Relations & Filings

Entera Bio Ltd. is a clinical-stage company developing orally delivered peptide and protein replacement therapies. The company leverages its proprietary N-Tab™ technology platform, which is designed to stabilize peptides in the gastrointestinal tract and promote their absorption into the bloodstream, offering a tablet-based alternative to injections. Its development pipeline targets significant unmet medical needs. Key programs include EB613, an oral teriparatide (PTH(1-34)) for postmenopausal women with high-risk osteoporosis, and EB612 for patients with hypoparathyroidism. Other programs include an oral oxyntomodulin for obesity and an oral GLP-2 peptide for rare malabsorption conditions such as short bowel syndrome.